Across all study participants, 34.4% of those treated with FB102 reached FVASI50 and 12.5% attained FVASI75 at week 24.
Phase transformations—in which a material changes from one crystal structure to another, thereby acquiring dramatically ...
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of Dominic Borie, M.D., ...
Globally recognized leader in early-phase oncology clinical development and experimental therapeuticsStrengthens strategic ...
ASCO 2026 highlighted a shift toward precision-driven oncology R&D, where biomarkers, ctDNA, and integrated strategies guide ...
When Vera Therapeutics in-licensed atacicept from Merck KGaA about six years ago, patients with IgA nephropathy (IgAN) had no ...
Anthropic’s new Claude research reveals a hidden internal “global workspace” that resembles human conscious processing, ...
A newly found chain-reaction phase change in 2D MoTe2 lowers energy barriers, enabling faster control of electronic and ...
The experience of the GT3 Sport Cabriolet is only enhanced by the power-operated roof, but the big challenge will likely be ...
Forte Biosciences stock soars after early-stage data show FB102 significantly improves facial depigmentation in vitiligo with ...
Detailed price information for Cue Biopharma Inc (CUE-Q) from The Globe and Mail including charting and trades.
(NASDAQ: GTBP) said it has integrated AI-based tools across the discovery and engineering of its tumor-targeting NK cell engagers and multi-domain proteins, efficiency gains the company expects to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results